As the only oncology Cluster of Excellence at the University of Tübingen (UT), iFIT started it’s cancer research journey on January 1, 2019. Despite great progress, cancer remains one of the greatest medical challenges. Many tumor diseases are still only detected at an advanced, metastatic stage, mostly incurable. iFIT is dedicated to precisely target these therapy-resistant tumors. Researchers from several disciplines work together to find new vulnerabilities in tumor cells, develop individual therapies, and visualize their effects directly in the body.
iFIT combines 3 complementary research areas: a) Functional target discovery, academic drug development and molecular tumor therapies b) Immunology and immunotherapies c) Molecular and functional multiparametric imaging. In the 1st funding period, researchers were able to successfully test several active substances, antibodies, and vaccine therapies first-in-human. In addition, 4 spin-offs emerged from iFIT, and over 50 patents attest to the cluster’s innovative strength. iFT has a strong global network of partners, including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Cancer Research UK, to name just a few. The success of iFIT contributed to the selection of the UT as a new site within the National Center for Tumor Diseases (NCT), which funds clinical trials.
(Planned) Support Activities for Postdocs
iFIT Early-Career Support Program (ECSP) | Athene Grant: Promoting Female Postdoc Scientists | iFIT PhD Program | Advanced Grant Challenge | Junior Grant Challenge | iFIT Workshops of Excellence | Talent Academy | iFIT Annual Junior Academy Retreat | Networking Events | Tübingen Program for the Advancement of Women (TÜFF) | Annual Scientific Retreat | Lab Internships | iFIT Travel Support for International Conferences
Recruiting
Open positions are listed at the bottom of the Cluster’s website.
Find out more
Website | Newsletter | LinkedIn | iFIT Distinguished Lecture Series in Tübingen
